Patients with intracerebral hemorrhage who were admitted to acute stroke units were randomly assigned to either 1 gram intravenous tranexamic acid followed by an 8-hour infusion of 1 gram tranexamic acid or matched placebo.
While developing the hematoma expansion prediction score, associations between hematoma expansion and blend sign, any intrahematoma hypodensity, and time from onset to noncontrast computed tomography <2.5 hours were found.
Investigators performed a pre-planned secondary analysis of the open-label, randomized Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 study, specifically on the magnetic resonance images obtained during the intensive blood pressure lowering portion of the trial.
The investigators of this study did not compare pre- or post-hemorrhage data, precluding their ability to determine the applicability of the findings for improving clinical practice.
Investigators conducted a meta-analysis of trials that reported functional outcomes and mortality rates among patients with intracerebral hemorrhage following intensive blood pressure lowering.
Further research may be necessary to better understand the pathophysiologic mechanisms involved in perihemorrhagic edema evolution and ICH.
For patients with CKD and atrial fibrillation, anticoagulants are linked with an increased risk of ischemic stroke.
Outcomes in intracerebral hemorrhage are less severe in patients with prior NOAC use.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
